Regulatory intelligence for seed-stage biotech
One or two programs, both preclinical, and an IND somewhere on the horizon that the next round depends on. Nobody at this stage is buying enterprise reg-intel software, but the decisions you're making right now about IND-enabling studies are among the most expensive you'll ever make. This is a guide to getting them right on a seed budget.
What the regulatory job actually is at this stage
There is no regulatory department. There's a founding scientist, possibly a CSO who has done this once before, and a consultant on a few hours a month. And yet the questions in front of you are the ones that set the cost and timeline of everything that follows:
- Which IND-enabling studies do we actually need? The tox package, the GLP question, the species selection. This is where a seed-stage company most often over-spends or under-delivers, and the difference between the two is precedent.
- What's our first-in-human design going to look like? Starting dose and its justification, dose escalation, the patient-or-healthy-volunteer question for your modality.
- CMC for a first clinical batch: what has FDA actually accepted at IND stage for a product like yours, as opposed to what the guidance describes for a commercial process.
- Do we ask for a pre-IND meeting, and what do we ask in it? A pre-IND meeting is a small number of questions you get to ask once. Which questions are worth the slot depends entirely on what the agency has already answered for others.
- Is our pathway what we think it is? Designation eligibility, whether a modality precedent exists at all, whether the comparator we assumed is the comparator FDA will assume.
Two things make these hard in a way that money can't immediately fix. First, the cost of being wrong is asymmetric and lands later: an IND-enabling package designed off a guidance document, without checking what precedent shows, produces a clinical hold or an information request twelve months after you spent the money. Second, guidance documents don't answer these questions. Guidance describes what's generally expected. What you need is what an agency accepted from the last handful of programs that look like yours, and for a novel modality, "look like yours" requires actually reading them.
There's also a fundraising dimension nobody puts in a buyer's guide: your ability to describe a credible, precedent-grounded regulatory path is part of the diligence. "We'll figure out the tox package later" reads very differently from "here's what the last four programs in this modality did, and here's where we differ and why."
Methodology & scoring
Facts from public materials as of August 2026, plus what scientist-founders and first-time CSOs tell us in our own conversations.
- Preclinical and IND-stage precedent — review packages, protocols, tox and CMC sections, designation records
- Traceability — does a claim open to the underlying page or passage?
- Cost at seed stage — including whether a free tier gets you real work
- Usable without a regulatory specialist — can a scientist-founder get a defensible answer
- Judgment — does it help decide, or only inform
We score ourselves 2 of 4 on judgment on purpose. Rhizome tells you what the agency has accepted; deciding what your program should do with that is a human call, and at this stage it's usually a call you want an experienced human to make with you.
Ranked for a preclinical company on a seed budget
Rhizome AI
Best precedent research for the money at seed stageRhizome is a focused, AI regulatory coworker: what has your regulator said and decided, and what does that mean for your program. At seed stage the payoff is concrete and mostly about avoiding expensive mistakes. Ask what tox packages supported INDs for your modality, what starting-dose justifications FDA accepted for a first-in-human of this type, or which pre-IND questions similar programs actually asked, and the agents read the review packages, protocols, and approval records where those answers live, hundreds of documents on a hard question, with every claim opening to the exact passage.
The corpus is the reason exhaustiveness is possible: >45 million documents across >75 health-authority databases in >12 markets as of August 2026, on pace for >150 databases and >25 markets by year end, with every scanned page processed, which matters here because the tox and CMC detail you want is buried inside review packages that were never designed to be searched. Nothing gets substantiated from model memory; we benchmark our agents on that discipline, and no hallucinations have been reported in 18 months — a track record, not a guarantee, which is exactly why every claim is openable.
Practically: there's a free tier, pricing is published, and you start on a card checkout that takes a minute. The honest pitch at this stage isn't efficiency — it's that a company of twelve people can walk into a pre-IND meeting with the same precedent base a large pharma would bring.
A regulatory consultant, a few hours a month
Best judgment per dollar, and worth itSay this plainly: at seed stage, a good consultant is often the highest-leverage regulatory spend you have. They've seen INDs cleared and INDs held, they know how a division thinks, and for a first-time founder that pattern recognition is worth more than any tool. If you can only do one thing, talk to someone experienced.
The limit is arithmetic, and it has nothing to do with competence. A few hours a month buys judgment; it doesn't buy exhaustive reading, and nobody is billing you for the twenty-review-package scan that would tell you what the field actually does. And the budget paradox is sharpest here: a five-figure consulting engagement is a familiar line item, a three-figure software subscription somehow needs justifying. Hours are the most expensive way to do document recall and the cheapest way to buy judgment. The combination is the answer: bring the precedent, buy the judgment.
General AI alone (ChatGPT, Claude, Gemini, Copilot)
Where every seed-stage team starts, and it's fine up to a pointYou already have it, it costs nothing extra, and for learning the vocabulary and shape of the process it's genuinely useful. Nobody should pretend a founding scientist won't start here.
The danger at this stage is specific: general assistants sound most confident exactly where you're least able to check them. They answer from memory plus a shallow web pass, and the review packages that contain real IND precedent are largely scanned PDFs their crawlers don't reach, so you get a plausible, guidance-flavored answer about what's "typically" required, with citations that often don't survive being opened. Designing a tox package off that is how a seed round gets spent on the wrong studies. Copilot has the additional quirk of grounding in your own tenant, which for questions about the outside world is precisely backwards.
Reading FDA and EMA yourself
Free, real, and slower than you can affordDrugs@FDA, the EMA site, ClinicalTrials.gov, and a weekend. Everything is public and every citation is true by construction, and for one or two specific programs you want to understand deeply, this is time well spent. It stops working as a strategy when the question is "what does the field do," because that means reading twenty packages, and you have a company to run.
Enterprise suites (Cortellis, IQVIA Regulatory Intelligence)
Good products, wrong stageBoth are legitimate and both will be relevant to you eventually: Cortellis for standing coverage across 80+ markets, IQVIA Regulatory Intelligence for current requirements across 110+ countries and regions. Neither is shaped for a company with two preclinical programs and a US-first plan: the value is global standing coverage you don't need yet, the entry is a custom quote and a procurement conversation, and the content covers what's required, while the half of your question that's actually hard right now is what was accepted.
Revisit when you have a portfolio and a department.
How to pick at seed stage
Leveraged by large pharma, independent consultants, and everyone in between
“Last time we did this research, we spent weeks. Rhizome found the answer immediately.”
“Chetan idk what kind of magic you all did here, it's so good!”
“I want this. I'm really impressed by the quality of the information and the level of detail.”